At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but ...
The top 5 most-read obesity articles on AJMC.com in 2025 include conversations on the costs and coverage of glucagon-like ...
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ...
The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health. One of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback